Factors associated with ischemic stroke during aspirin therapy in atrial fibrillation: analysis of 2012 participants in the SPAF I-III clinical trials. The Stroke Prevention in Atrial Fibrillation (SPAF) Investigators.
about
Oral anticoagulants versus antiplatelet therapy for preventing stroke in patients with non-valvular atrial fibrillation and no history of stroke or transient ischemic attacksOral anticoagulants versus antiplatelet therapy for preventing stroke in patients with non-valvular atrial fibrillation and no history of stroke or transient ischemic attacksAntiplatelet therapy for preventing stroke in patients with non-valvular atrial fibrillation and no previous history of stroke or transient ischemic attacksAnticoagulants or antiplatelet therapy for non-rheumatic atrial fibrillation and flutterOral anticoagulants for preventing stroke in patients with non-valvular atrial fibrillation and no previous history of stroke or transient ischemic attacksArrhythmias in womenEpidemiology, diagnosis, and management of atrial fibrillation in womenOutcomes in the management of atrial fibrillation: clinical trial results can apply in practiceEffects of low-dose warfarin and aspirin versus no treatment on stroke in a medium-risk patient population with atrial fibrillationA cautionary note on data sources for evidence-based clinical decisions: warfarin and stroke preventionAtrial Fibrillation: Epidemiology, Pathophysiology, and Clinical Outcomes.Thrombosis and antithrombotic therapy in womenSex Differences in Outcomes among Stroke Survivors with Non-Valvular Atrial Fibrillation in China.Sex-specific responses to stroke.Antiplatelet therapy for preventing stroke in patients with non-valvular atrial fibrillation and no previous history of stroke or transient ischemic attacks.Oral anticoagulants for preventing stroke in patients with non-valvular atrial fibrillation and no previous history of stroke or transient ischemic attacks.Safe use of antithrombotics for stroke prevention in atrial fibrillation: consideration of risk assessment tools to support decision-makingStroke prevention in atrial fibrillation.Anticoagulants or antiplatelet therapy for non-rheumatic atrial fibrillation and flutter.New insights into the mechanisms and management of atrial fibrillationClinical characteristics and impact of diabetes mellitus on outcomes in patients with nonvalvular atrial fibrillation.Sex- and gender-specific research priorities for the emergency management of heart failure and acute arrhythmia: proceedings from the 2014 Academic Emergency Medicine Consensus Conference Cardiovascular Research Workgroup.Anticoagulants for atrial fibrillation: why is the treatment rate so low?Atrial fibrillation, stroke, and anticoagulation in Medicare beneficiaries: trends by age, sex, and race, 1992-2010.Statin use is associated with lower risk of atrial fibrillation in women with coronary disease: the HERS trial.Estrogen and neuroprotection: from clinical observations to molecular mechanisms.Atrial fibrillation: relation between clinical risk factors and transoesophageal echocardiographic risk factors for thromboembolismRole of oral anticoagulation in management of atrial fibrillation.Assessment of CHADS2 and CHA 2DS 2-VASc scores in obstructive sleep apnea patients with atrial fibrillation.Stroke with atrial fibrillation or atrial flutter: a descriptive population-based study from the Brest stroke registry.Antithrombotic therapy for atrial fibrillation: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.Evaluation of survival and ischaemic and thromboembolic event rates in patients with non-valvar atrial fibrillation in the general population when treated and untreated with warfarin.Association of Smoking, Alcohol, and Obesity with Cardiovascular Death and Ischemic Stroke in Atrial Fibrillation: The Atherosclerosis Risk in Communities (ARIC) Study and Cardiovascular Health Study (CHS)Ximelagatran: a new antithrombotic option in atrial fibrillation.Ximelagatran: an oral direct thrombin inhibitor.Warfarin in atrial fibrillation patients with moderate chronic kidney diseaseAssessment of female sex as a risk factor in atrial fibrillation in Sweden: nationwide retrospective cohort study.The epidemiology of atrial fibrillation in elderly persons: the tip of the iceberg.Gender differences in the risk of ischemic stroke and peripheral embolism in atrial fibrillation: the AnTicoagulation and Risk factors In Atrial fibrillation (ATRIA) study.Atrial fibrillation: management for the geriatric patient.
P2860
Q24244298-D2281631-E2C6-4B0E-A3C1-51D08E8BF6E0Q24244742-12151A4F-1126-47DF-B7A0-B62784E7A9EDQ24245569-9168DD66-5072-436E-A68D-D880933A6D1EQ24245613-CDD557FA-BE5A-4D4E-A882-F4EDD5E080CEQ24246644-17A0691D-9213-4636-9E22-42F74A54E857Q26823099-FCF152CE-23BC-4B27-B1E3-B32EB4A51CBAQ28083655-896A2741-AED5-46E7-A3F6-2262CE6F7442Q28188553-864C086A-835A-41F9-A655-5D8F6148A30BQ28196521-39695FD9-555F-47F8-AD28-02AF1A691B9BQ28218659-FE3A46D4-91BF-47E2-9AD5-A88D5C0CC82CQ30234626-20A5D806-3AE1-41C2-9485-59B3B5765C02Q33569283-8F64A904-7035-4DBD-9D54-63777041982AQ33606961-D571A15F-0AD8-4899-9BD7-7DFDDC3472C3Q33685081-00721ADE-1DAC-42EC-AA5B-5934F0D0A46DQ33908359-39762FD4-BEE6-4CA1-A306-77B996E6FC97Q33908366-756E1064-72DF-4FB1-A9EC-00D84C2363E9Q33949571-B26F211C-A62A-4338-AF27-D4172688BEAFQ34027391-9476B1B9-61E1-478E-8CA9-943C22BABEC9Q34202452-4EC975B7-96C6-49B0-B491-3C0AA8E2985DQ34289414-968A6DA7-A912-4269-B66C-0B5329C91C5EQ34774249-990B3039-76D8-4B0A-9846-F5518AF70327Q34836591-8AE3A4EB-26A2-47A3-8EA3-F942BD002207Q34958223-5B1BD528-D398-44DD-8460-9FC832D8882EQ35021837-003D308F-BD3C-4C5C-A89A-73E763996A90Q35207701-700EA002-BDAB-4952-9013-265144684CE3Q35236454-784447BD-9B12-4C3E-ADE2-FAA8B3E4C312Q35580787-0384A901-DE78-4300-979E-02B5D3D29CBBQ35582611-E549F20F-AD37-4AD9-9895-4D9158B3DEA9Q35597696-7943089B-23E4-4A4D-92D3-F56DB5FD8C18Q35660429-596D226C-5D89-41D9-8049-ED5ADE9BEDE8Q35752573-DCA071AA-98E6-4E4B-A400-75A135FB3A0EQ35771232-CDDEC213-11E7-4636-9C83-0DA07E839544Q35891480-30655ED6-315A-4C86-8CDC-03551953BA6DQ35892171-89C3F067-E29C-434C-91A6-03D88909A83EQ35895188-0878FA22-0C2A-4AEC-BAD1-E4868E0F98D7Q35985876-7EE81B45-47F6-45EE-8227-EC596190CE4DQ36001150-755C16B0-C359-46A5-B464-53D24845F897Q36077771-27D428D4-B1C4-4902-9F97-D6BDC6E06831Q36255692-9CFEC668-AFC3-4AE8-8443-08645699C3F0Q36296070-8C388680-C170-4E65-BA75-C665559B3F3B
P2860
Factors associated with ischemic stroke during aspirin therapy in atrial fibrillation: analysis of 2012 participants in the SPAF I-III clinical trials. The Stroke Prevention in Atrial Fibrillation (SPAF) Investigators.
description
1999 nî lūn-bûn
@nan
1999 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
1999 թվականի հունիսին հրատարակված գիտական հոդված
@hy
1999年の論文
@ja
1999年論文
@yue
1999年論文
@zh-hant
1999年論文
@zh-hk
1999年論文
@zh-mo
1999年論文
@zh-tw
1999年论文
@wuu
name
Factors associated with ischem ...... illation (SPAF) Investigators.
@ast
Factors associated with ischem ...... illation (SPAF) Investigators.
@en
type
label
Factors associated with ischem ...... illation (SPAF) Investigators.
@ast
Factors associated with ischem ...... illation (SPAF) Investigators.
@en
prefLabel
Factors associated with ischem ...... illation (SPAF) Investigators.
@ast
Factors associated with ischem ...... illation (SPAF) Investigators.
@en
P2093
P356
P1433
P1476
Factors associated with ischem ...... illation (SPAF) Investigators.
@en
P2093
L A Pearce
R M Rothbart
R W Asinger
P304
P356
10.1161/01.STR.30.6.1223
P407
P577
1999-06-01T00:00:00Z